trastuzumab sold brand name kadcyla antibodydrug conjugate consisting humanized monoclonal antibody trastuzumab herceptin covalently linked cytotoxic agent trastuzumab alone stops growth cancer cells binding receptor whereas trastuzumab emtansine undergoes receptormediated internalization cells catabolized lysosomes catabolites released subsequently bind tubulin cause mitotic arrest cell trastuzumab binding prevents homodimerization heterodimerization receptor ultimately inhibiting activation mapk cellular signalling pathways monoclonal antibody targets overexpressed cancer cells conjugate delivers cytotoxic agent specifically tumor conjugate abbreviated emilia clinical women advanced positive breast cancer already resistant trastuzumab alone improved median overall survival months months vs months compared combination lapatinib based trial us food drug administration fda approved marketing february trastuzumab emtansine developed genentech manufactured united states trastuzumab emtansine approved specifically treatment metastatic breast cancer mbc patients treated previously trastuzumab taxane paclitaxel docetaxel already treated mbc developed tumor recurrence within six months adjuvant approval based emilia phase iii clinical trial compared trastuzumab emtansine versus capecitabine xeloda plus lapatinib tykerb people unresectable locally advanced metastatic breast cancer previously treated trastuzumab taxane trial showed improved progressionfree survival patients treated trastuzumab emtansine median vs months along improved overall survival median vs months clinical trials common adverse effects trastuzumab emtansine fatigue nausea musculoskeletal pain thrombocytopenia low platelet counts headache increased liver enzyme levels severe adverse events identified emilia trial included hepatotoxicity liver damage including rare cases liver failure hepatic encephalopathy nodular regenerative hyperplasia heart damage dysfunction left ventricle interstitial lung disease including acute interstitial pneumonitis thrombocytopenia peripheral overall trastuzumab emtansine better tolerated control treatment combination lapatinib tykerb capecitabine xeloda patients trastuzumab emtansine group experiencing severe toxic effects versus received lapatinibcapecitabine furthermore fewer patients stop treatment due adverse effects lapatinib anemia low platelet counts peripheral neuropathy common among patients received trastuzumab emtansine whereas heart damage gastrointestinal effects vomiting diarrhea stomatitis common united states trastuzumab emtansine carries black box warnings liver toxicity heart damage reduction left ventricular ejection fraction fetal harm given pregnant trastuzumab emtansine antibodydrug conjugate adc combination monoclonal antibody smallmolecule drug molecule trastuzumab emtansine consists single trastuzumab molecule several molecules cytotoxic maytansinoid smcc succinimidyl heterobifunctional crosslinker type chemical reagent contains two reactive functional groups succinimide ester maleimide succinimide group smcc reacts free amino group lysine residue trastuzumab moleculefailed verification maleimide moiety smcc links free sulfhydryl group forming covalent bond antibody trastuzumab molecule may linked zero eight molecules binds plus ends cellular microtubules thereby inhibits cell division target tumor trastuzumab emtansine approved united states treatment adults metastatic breast cancer previously received trastuzumab taxane separately referred clinical research trastuzumab emtansine reviewed fdas priority review safety effectiveness trastuzumab emtansine evaluated clinical study patients randomly assigned receive trastuzumab emtansine lapatinib plus capecitabine another chemotherapy patients received treatment either cancer progressed side effects became study designed measure progressionfree survival length time patients lived without cancer progressing overall survival length time patients lived results showed patients treated trastuzumab emtansine median progressionfree survival months compared months patients treated lapatinib plus median overall survival months trastuzumab emtansine group months lapatinib plus capecitabine us food drug administration fda approved trastuzumab emtansine february granted application kadcyla fda granted application trastuzumab emtansine priority review breakthrough therapy trastuzumab emtansine approved trastuzumab emtansine approved united states adjuvant treatment patients early breast cancer ebc residual invasive disease neoadjuvant taxane trastuzumabbased approval based katherine randomized multicenter openlabel trial patients breast tumor samples required demonstrate overexpression defined ihc ish amplification ratio determined central laboratory using ventanas pathway rabbit monoclonal primary antibody inform dual ish dna probe cocktail patients required neoadjuvant taxane trastuzumabbased therapy residual invasive tumor breast andor axillary lymph patients received radiotherapy andor hormonal therapy concurrent study treatment per local patients randomized receive trastuzumab emtansine mgkg intravenously trastuzumab mgkg intravenously day cycle trials primary endpoint invasive diseasefree survival idfs defined time date randomization first occurrence ipsilateral invasive breast tumor recurrence ipsilateral local regional invasive breast cancer recurrence distant recurrence contralateral invasive breast cancer death median followup months trial demonstrated statistically significant improvement idfs patients received trastuzumab emtansine compared received trastuzumab hr ci overall survival data mature time idfs uk trastuzumab emtansine recommended use national health service advisory body nice reportedly acceptable pricing agreement could reached originally cost nice estimated cost per well usual maximum funded english nhs cancer drugs fund january proposed remove approved secret discount agreed roche cancer drugs fund continue fund june nhs confederation nhs chief executive simon stevens announced nhs would offering trastuzumab emtansine limited number women striking deal roche trastuzumab emtansine approved united states generic name adotrastuzumab rather original united states adopted name usan issued trastuzumab trastuzumab antibody emtansine refers linkerdrug ado prefix added request fda help prevent dispensing preclinical development clinical trials drug also known codename emtansine abbreviated codename since clinical trials httpsenwikipediaorgwikitrastuzumabemtansine